PinnedHow to value an early-stage listed Biotech company with no revenues?Disclaimer: The objective of this write up ( a part of my MBA case study)is for the reader to understand how financial valuation is done…Jun 25, 2023Jun 25, 2023
How Pooled Pension Capital could transform drug development finance by bridging the valley of death…Disclaimer and Personal Note6d ago6d ago
Investment Memo 3 — ADC Innovation: Spotlight on Myricx Bio’s Novel ApproachDisclaimer: This memo is for research purposes and reflects my interest in writing an investment blog. It should not be considered a…Nov 12Nov 12
GPay’s Evolution in India’s Digital Finance RevolutionIn the rapidly evolving landscape of digital finance, Google Pay (GPay) stands at a pivotal crossroads. Originally conceived as a digital…Sep 13Sep 13
Investment Memo Biotech : Case 2Company Overview: Scenic Biotech is a pioneering biopharmaceutical company leveraging its proprietary Cell-Seq platform to discover and…Jul 22Jul 22
Exploring Innovative Business Models in Biotech: The Case of Royalty PharmaThe biopharmaceutical industry is marked by high risks, significant R&D costs, and the potential for substantial returns. Among the various…Jun 13Jun 13
Mastering Your Startup’s Cap Table: A Step-by-Step Practical Guide to build Cap Table from Seed to…You’ve probably read tons of articles about the different rounds of VC funding and all the associated terms, but how often do you come…May 29May 29
Investment Memo — Biotech: Case 1Disclaimer: An investment memo on Laverock Therapeutics, leverage their own GEiGS platform. This memo is for research purposes and…May 27May 27
“Strategic Acquisitions in Pharma: How Industry Trends and Competitor Actions Shape the Future to…Recently, the pharmaceutical industry has witnessed a series of notable acquisitions, particularly in specific areas such as…May 20May 20
Opportunities in Rare Diseases: The Economics of Orphan DrugsIn the realm of pharmaceuticals, the pursuit of treatments for rare diseases stands as both a noble endeavour and a complex business…Feb 29Feb 29
